Vilon: what the research shows

  • By Reed Calder
  • Last reviewed Nov 12, 2026
  • 31 studies and official documents checked

In short

Vilon is a lab-made peptide of two amino acids, lysine and glutamic acid (Lys-Glu, or KE), from the St. Petersburg group of Vladimir Khavinson. It is sold online as an “immune bioregulator” and an anti-aging peptide. We found three small Russian reports in people, two in type 1 diabetes and one in older cancer patients, and their abstracts give almost no numbers. In mice and rats it lowered chemical-induced tumors, but in mice bred to get breast cancer it raised cancer. The 20 to 40% longer life that sellers quote isn’t in any abstract we read. In dishes it loosened tightly packed DNA in older people’s immune cells. Khavinson co-authored 17 of the 20 studies we cite, and no registered trial lists Vilon. It isn’t FDA-approved.

EvidenceCellAnimalHumanthree small Russian reports in people; abstracts only

You’ll often read that Vilon extends mouse lifespan 20 to 40%, cuts insulin needs by 9 units, reverses chromatin aging, normalizes telomeres, and is the shortest bioactive peptide. This page covers what it is, what each study tested, why the mouse cancer results point both ways, and where it stands legally.

Names and forms you’ll see

The names on Vilon products
Name What it is Studied in people?
Vilon, KE, Lys-Glu The trade name, the letter code and the amino-acid names for the same dipeptide: lysine joined to glutamic acid (Khavinson et al., 2021) Three small reports
Lysylglutamic acid The chemical name in the FDA’s substance registry and in PubChem, where “Vilon” is listed as a name for it Same
Thymomimetic, immune bioregulator Labels the Russian papers use: a short peptide said to mimic thymus factors (Kuznik et al., 2007) Same
Thymalin A thymus extract, a mixture. The group names KE and EW as its active substances (Linkova et al., 2023). Thymalin isn’t Vilon Not this page
Vials and powders Forms sold online under the Vilon name No study of these found
KED, EW, AEDG Other Khavinson peptides with similar letters: Vesugen, Thymogen and Epitalon. Vilon is KE only Different studies

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The registry also holds a dihydrate record under its own number, 94729-48-3. A seller catalog lists a third number, 79443-38-8, with the formula C11H21N3O6; neither matches the registry’s entry for the dipeptide.

Vilon CAS numbers
Form CAS number Registry record
Vilon (Lys-Glu) 45234-02-4 FDA GSRS

What Vilon is

Vilon is two amino acids bonded together: lysine, then glutamic acid. By its PubChem record it is C11H21N3O5 and weighs 275.30 daltons. Khavinson’s group lists it for “regulation of immune system function,” along with antioxidant, stress-protective and anti-aging effects (Khavinson et al., 2021), and names KE and EW as the active substances of Thymalin, a thymus extract (Linkova et al., 2023).

The idea behind it is that very short peptides enter a cell’s nucleus, contact DNA and change which genes are switched on. For KE, what supports that is cell work and computer modeling: a 2023 model suggests KE fits the DNA sequences GCGG and GGGC, which occur in the promoters of the SIRT1, PARP1 and PARP2 genes (Khavinson et al., 2023).

None of that chain has been shown in a living person.

What has been studied

In people: three small Russian reports, 2005 to 2007

  • Type 1 diabetes, clotting, 2006. In patients with type 1 diabetes in a destabilized phase, Vilon reduced or removed a chronic clotting disorder (DIC syndrome). The effect was weaker in older patients with severe disease. PubMed lists it as a randomized controlled trial; the abstract gives no group sizes, dose or numbers (Kuznik et al., 2006).
  • Type 1 diabetes, immunity and insulin, 2007. Added to usual care in older patients, Vilon was followed by more of two natural anticoagulants (antithrombin III and protein C) and more clot breakdown. In most cases the insulin dose needed to steady blood sugar was lower. T-helper and NK cells fell, and active T cells, B cells and IgA were reported as normalized. The abstract gives no patient count and no unit figure (Kuznik et al., 2007).
  • Older cancer patients, 2005. Vilon was added to the treatment of older patients with stage III colon and rectal cancer. The authors call it pioneer experience and say preliminary results suggest it may raise 2-year survival and cut complications. The abstract gives no numbers, and Khavinson is a co-author (Ias’kevich et al., 2005).
  • What we couldn’t read. We saw only abstracts; we found no English full text and no human study from outside Russia. The developers’ 2013 review summarizes their clinical work (Khavinson et al., 2013).
  • No registered trial. ClinicalTrials.gov lists no study under Vilon (ClinicalTrials.gov search).

EvidenceCellAnimalHumanthree reports; abstracts only; no placebo or blinding described

In mice and rats

  • Lifespan, 2000 and 2001. A 2000 report says female CBA mice given Vilon from month 6 were more active, had lower body temperature, lived longer and had fewer spontaneous tumors, with no ill effects on development; its abstract has no numbers (Khavinson et al., 2000). In a 2001 paper with a similar design, Lys-Glu raised activity and lowered lung adenomas, but the survival gains in the abstract (5.3% for mean survival, 10 months for the longest-lived) were with Epitalon, not Lys-Glu (Anisimov et al., 2001). A second 2000 paper’s title says Vilon increases life span; PubMed holds no abstract for it (Khavinson et al., 2000 (Dokl)).
  • Tumors that fell, 2001 and 2005. In rats given a bladder carcinogen, tumors appeared in 56% on Vilon against 75.5% on saline, with half as many early changes (Pliss et al., 2001). In mice given the chemical dimethylhydrazine, tumors appeared in 14.3% of those alive at week 46 against 60% of controls (Pliss et al., 2005).
  • Tumors that rose, 2002. In mice bred to develop breast cancer (HER-2/neu), Vilon raised the share getting cancer, shortened the time to the first tumor and raised the number of tumors, all at p below 0.05, while Epitalon reduced the number and size of tumors (Anisimov et al., 2002). A second report in the same model found two or more tumors in 95% on Vilon, 75% on saline and 56% on Epitalon, and lung metastases 2.6 times as common as with Epitalon (Alimova et al., 2002).
  • Radiation, 2001 and 2002. In rats given 6 Gy of whole-body radiation, Vilon raised thymocyte division and stem-cell activity in the intestine. In a low-dose model of radiation aging, it partly slowed aging of the thymus and spleen (Khavinson et al., 2001; Kniaz’kin et al., 2002).
  • Gene activity, 2002. In mouse heart, Vilon changed 36 of 15,247 gene clones by more than two-fold; Epitalon changed 98 and the pair 144 (Anisimov et al., 2002 (heart)).

EvidenceCellAnimalHumanfemale CBA mice, HER-2/neu mice and rats; Khavinson a co-author on 9 of 10 studies

In dishes

  • Old people’s immune cells, 2004. In cultured lymphocytes from older people, Vilon unrolled tightly packed chromatin, reactivated ribosomal genes and released genes silenced by age-related condensation, and left the structural chromatin near the center of the chromosomes alone (Lezhava et al., 2004). White cells from people aged 75 to 88 responded the same way to Vilon and four other peptides (Khavinson et al., 2004).
  • Stem cells, 2020 and 2023. In human mesenchymal stem cells at nanomolar concentrations, KE and two other short peptides raised IGF1 gene activity 3.5- to 5.6-fold and NF-kB gene activity in both aging models; KE alone raised FOXO1 about two-fold in one model (Ashapkin et al., 2020). In 2023, SIRT1 gene activity rose 6-fold and protein 8.2-fold in “young” cells, while PARP1 and PARP2 gene activity fell about 2.1-fold and protein 4.7- to 5.3-fold during aging (Khavinson et al., 2023).
  • Skin cells and white blood cells, 2020 and 2022. In aging human skin cells, KE lowered IL-1, NF-kB and TGF-beta synthesis and raised sirtuin-6 (Fridman et al., 2020). In human THP-1 monocytes, Vilon and four other Khavinson products lowered the TNF and IL-6 made after a bacterial stimulus (Avolio et al., 2022).
  • Thymalin’s parts, 2023. Modeling and gene-activity work on KE and EW, the two dipeptides the group names as Thymalin’s active substances, framed around COVID-19 pathways (Linkova et al., 2023).

EvidenceCellAnimalHuman

Khavinson is a co-author on 17 of the 20 studies we cite. The other three are Russian reports: two from Kuznik’s diabetes group and one radiation paper. We found no replication from an independent lab (Kuznik et al., 2006; Kuznik et al., 2007; Kniaz’kin et al., 2002).

The usual claims, checked

Common Vilon claims vs the studies
Claim Verdict What the studies found
It reverses chromatin condensation and reactivates silenced genes Supported In cultured lymphocytes from older people it unrolled tightly packed chromatin and reactivated ribosomal genes (Lezhava et al., 2004; Khavinson et al., 2004). Both are dish studies from one network; none measured chromatin in a living animal or person
It extends lifespan by 20 to 40% in mice Mixed No abstract we found gives that figure. A 2000 report says treated mice lived longer, without a number (Khavinson et al., 2000). In the 2001 mouse paper the survival gains were with Epitalon, not Lys-Glu (Anisimov et al., 2001). Another 2000 paper’s title claims longer life, but PubMed holds no abstract (Khavinson et al., 2000 (Dokl))
It prevents or inhibits tumors Mixed In rats given a bladder carcinogen, tumors appeared in 56% against 75.5% (Pliss et al., 2001), and in mice given dimethylhydrazine in 14.3% against 60% of those alive at week 46 (Pliss et al., 2005). In mice bred to develop breast cancer it raised cancer incidence and shortened the time to tumors (Anisimov et al., 2002; Alimova et al., 2002)
It helps people with cancer Mixed One 2005 Russian report added it to treatment of older patients with stage III colon and rectal cancer and called the preliminary results promising; the abstract gives no numbers (Ias’kevich et al., 2005). The breast-cancer mouse result went the other way
It cuts insulin needs in type 1 diabetes (“9 units, 150 patients”) Mixed In one 2007 report of Vilon added to diabetes care, the insulin dose needed was lower in most cases (Kuznik et al., 2007). Neither the patient count nor a unit figure appears in the abstracts, and we found no full text, so the 150 and the 9 you may read online are unchecked
It restores the thymus and boosts immunity Mixed In irradiated rats it raised thymocyte division and partly slowed radiation aging of the thymus and spleen (Khavinson et al., 2001; Kniaz’kin et al., 2002). In diabetes patients, immune markers were reported as normalized (Kuznik et al., 2007). No study counted infections, vaccine response or illness
It calms inflammation by acting on NF-kB Mixed It lowered NF-kB, IL-1 and TGF-beta synthesis in aging skin cells and TNF and IL-6 in stimulated monocytes (Fridman et al., 2020; Avolio et al., 2022), but raised NF-kB gene activity in stem cells (Ashapkin et al., 2020). All three are dish studies
It lengthens or normalizes telomeres Untested We found no study that measured telomere length after Vilon
It improves skin and collagen Untested In aging human skin cells in a dish, KE lowered inflammatory signals and raised sirtuin-6 (Fridman et al., 2020). We found no study of Vilon on the skin of an animal or person
It repairs the gut, eyes and brain Untested In irradiated rats it raised stem-cell activity in the intestine (Khavinson et al., 2001). We found no Vilon study of the retina or of nerve cells
It balances clotting and lowers clot risk Mixed In two small Russian reports in type 1 diabetes, clotting measures improved: more antithrombin III and protein C and more clot breakdown, less so in older patients with severe disease (Kuznik et al., 2006; Kuznik et al., 2007). No study counted clots, strokes or other events
It is safe, with no side effects Mixed Treated mice showed no ill effects on development, but in breast-cancer-prone mice it raised cancer (Khavinson et al., 2000; Anisimov et al., 2002). The human abstracts mention no side effects and don’t say whether anyone looked. We found no toxicity or dose-escalation study, so a claim that no lethal dose exists has no study behind it
Trials in surgical and dental patients showed good tolerance Untested We found no abstract of a Vilon trial in either group. A Russian review of dental care names Vilon among the thymic peptides it covers; its abstract gives no results for it (Pinelis et al., 2020)
It works better stacked with Epitalon Untested One mouse study gave both and counted gene-activity changes in the heart: 36 clones for Vilon, 98 for Epitalon and 144 for both (Anisimov et al., 2002 (heart)). No study measured health, lifespan or tumors for the pair
The online dose tables come from the human studies Untested The human abstracts give no dose, schedule or group size (Kuznik et al., 2006; Kuznik et al., 2007; Ias’kevich et al., 2005). The mouse studies used 0.1 to 1 microgram per mouse (Anisimov et al., 2001; Anisimov et al., 2002)
Its formula is C11H21N3O6 and its weight 291.30 Contradicted No. The FDA registry and PubChem give C11H21N3O5 and 275.30 for lysine joined to glutamic acid. The seller figure is one oxygen atom heavier
It is FDA-approved Contradicted No. The FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA), and its safety-risk page doesn’t name it (FDA, 2026)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

Vilon and Epitalon

Vilon compared with Epitalon in the same mouse and rat experiments
Vilon (Lys-Glu) Epitalon (Ala-Glu-Asp-Gly)
Amino acids Two Four
Female CBA mice, lifespan (2001) No survival gain in the abstract Mean survival up 5.3%, longest-lived up 10 months (Anisimov et al., 2001)
Breast-cancer-prone HER-2/neu mice (2002) More cancer, tumors sooner, more tumors Fewer and smaller tumors (Anisimov et al., 2002)
Rat bladder tumors (2001) Tumors in 56% against 75.5% No inhibitory effect recorded (Pliss et al., 2001 (Vopr Onkol))

The two peptides were tested side by side by the same group, and they didn’t behave alike. A result for one isn’t a result for the other. For Epitalon alone, see the Epitalon page; for the rest of the family, see the peptide bioregulators page.

What the studies used

Amounts used in the Vilon studies
Study What was tested Amount reported
Anisimov et al., 2001 Female CBA mice, lifespan and tumors 0.1 microgram per mouse for 5 consecutive days each month, from age 6 months until natural death
Anisimov et al., 2002; Alimova et al., 2002 Breast-cancer-prone HER-2/neu mice 1 microgram per mouse for 5 consecutive days each month, from age 2 months
Pliss et al., 2005 Mice given dimethylhydrazine 10 micrograms per kilogram
Pliss et al., 2001 Rats given a bladder carcinogen Not stated in the abstract
Kuznik et al., 2006; Kuznik et al., 2007; Ias’kevich et al., 2005 Three Russian reports in people Dose, schedule and group size not stated in the abstracts
Ashapkin et al., 2020 Human stem cells Nanomolar concentrations

A dose per mouse doesn’t convert into a dose for a person, and no study did that conversion. We found no blood-level or dose-finding study in any animal or person. These are amounts from studies, not advice for anyone to use.

Side effects and safety

  • In people. The three abstracts mention no side effects and don’t say whether anyone looked for them.
  • In animals. A 2000 report says long-term Vilon had no unfavorable effect on development, the estrous cycle or free-radical measures in mice (Khavinson et al., 2000). Against that, in breast-cancer-prone mice it raised cancer incidence and shortened the time to tumors (Anisimov et al., 2002).
  • Opposite tumor results. Tumors fell in rats and in mice given chemicals and rose in the breast-cancer-prone strain (Pliss et al., 2001; Pliss et al., 2005; Anisimov et al., 2002). The abstracts don’t explain why, and nobody has tested it in people.
  • No toxicity study. We found no dose-escalation or toxicology study of Vilon in any animal.
  • What is in the bottle. We found no independent analysis of Vilon vials or powders sold online, and some seller pages print the wrong formula and weight.
  • Not studied. Pregnancy, children, long-term use in people, people with cancer or autoimmune disease, and use with immune-suppressing drugs.

Side effects people report from online products aren’t covered here; they come from users, not studies.

Legal and approval status

  • Not an approved drug. The FDA’s approved-drug data return no product under Vilon or lysylglutamic acid (openFDA Drugs@FDA), and its page of bulk substances that may present significant safety risks doesn’t name it (FDA, 2026). The FDA substance registry lists it as lysylglutamic acid, which is a record of the chemical, not an approval.
  • No registered trial. ClinicalTrials.gov lists no study under Vilon (ClinicalTrials.gov search).
  • Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
  • Sport. The World Anti-Doping Agency’s 2026 list doesn’t name it, but its S0 class prohibits any substance with no government approval for human therapeutic use (WADA, 2026).
  • “Research use only” vials and any use in people aren’t approved.

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and registries:

  • The formula. Lys-Glu is C11H21N3O5 and 275.30. A page or a lab report quoting 291.30 or C11H21N3O6 has the wrong molecule or a copied error.
  • Whose study. Khavinson co-authored 17 of the 20 studies we cite. Ask whether anyone else has repeated them.
  • A lifespan percentage. “20 to 40% longer” needs a paper with that number; none of the abstracts we read has it.
  • Cancer, both ways. A page listing only the tumor-lowering results leaves out the breast-cancer mice, where Vilon raised cancer.
  • The human numbers. The three human reports are Russian abstracts without patient counts, so a “150 patients, 9 units” figure is unchecked.
  • Mice aren’t people. The doses are per mouse, and a page quoting them as a human amount has no study behind it.

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.

What’s still unknown

  • Whether Vilon does anything measurable in people, since the three reports give no numbers or described controls.
  • Whether the tumor-lowering results in rats and mice, or the cancer-raising result in HER-2/neu mice, say anything about people.
  • Whether it changes lifespan, telomeres, skin, gut, eyes or brain, which no study measured or no abstract quantifies.
  • Whether KE reaches the nucleus and contacts DNA in a living animal or person; the evidence is cell work and modeling.
  • Whether anyone outside the Khavinson network gets the same results.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention Vilon. We recheck every month. Last checked Nov 12, 2026.

We found no retracted, withdrawn or flagged studies that mention Vilon.

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Khavinson and Anisimov, 2000 Dokl Biol Sci No retraction or concern
Khavinson et al., 2000 Bull Exp Biol Med No retraction or concern
Anisimov et al., 2001 Mech Ageing Dev No retraction or concern
Khavinson et al., 2001 Bull Exp Biol Med No retraction or concern
Pliss et al., 2001 Bull Exp Biol Med No retraction or concern
Pliss et al., 2001 Vopr Onkol No retraction or concern
Kniaz'kin and Poliakova, 2002 Adv Gerontol No retraction or concern
Alimova et al., 2002 Vopr Onkol No retraction or concern
Anisimov et al., 2002 Int J Cancer No retraction or concern
Anisimov et al., 2002 Bull Exp Biol Med No retraction or concern
Khavinson et al., 2004 Bull Exp Biol Med No retraction or concern
Lezhava et al., 2004 Biogerontology No retraction or concern
Ias'kevich et al., 2005 Adv Gerontol No retraction or concern
Pliss et al., 2005 Vopr Onkol No retraction or concern
Kuznik et al., 2006 Adv Gerontol No retraction or concern
Kuznik et al., 2007 Adv Gerontol No retraction or concern
Khavinson et al., 2013 Adv Gerontol No retraction or concern
Pinelis et al., 2020 Adv Gerontol No retraction or concern
Ashapkin et al., 2020 Mol Biol Rep No retraction or concern
Fridman et al., 2020 Bull Exp Biol Med No retraction or concern
Khavinson et al., 2021 Molecules No retraction or concern
Avolio et al., 2022 Int J Mol Sci No retraction or concern
Linkova et al., 2023 Int J Mol Sci No retraction or concern
Khavinson et al., 2023 Adv Gerontol No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is Vilon peptide?

A lab-made peptide of two amino acids, lysine and glutamic acid (Lys-Glu, or KE), from Vladimir Khavinson’s group in St. Petersburg. Its chemical name is lysylglutamic acid (Khavinson et al., 2021; PubChem).

What is Vilon peptide used for?

It is sold as an immune and anti-aging peptide. The studies are three small Russian reports in people (two in type 1 diabetes, one in older cancer patients), mouse and rat experiments, and dish work (Kuznik et al., 2007; Ias’kevich et al., 2005; Anisimov et al., 2001).

What are the benefits of Vilon peptide?

Unproven. In rats and mice it lowered some chemical-induced tumors, and in dishes it loosened chromatin in older people’s immune cells. In people, one report says the insulin dose needed was lower in most cases, with no numbers in the abstract (Pliss et al., 2001; Lezhava et al., 2004; Kuznik et al., 2007).

Does Vilon peptide work?

Unknown in people. The three human reports are small Russian abstracts without numbers, and Khavinson co-authored 17 of the 20 studies we cite. We found no independent replication (Kuznik et al., 2007; Ias’kevich et al., 2005).

Is Vilon peptide safe?

Not shown. A 2000 report found no ill effects on development in treated mice, but in breast-cancer-prone mice it raised cancer, and we found no toxicity study (Khavinson et al., 2000; Anisimov et al., 2002).

What are the side effects of Vilon peptide?

Unknown. The human abstracts mention none and don’t say whether anyone looked. Side effects people report from online products come from users, not studies.

What is the Vilon peptide dosage?

We don’t give dosing advice. The mouse studies used 0.1 to 1 microgram per mouse for 5 consecutive days each month, and the human abstracts give no dose (Anisimov et al., 2001; Anisimov et al., 2002; Kuznik et al., 2007).

Does Vilon fight cancer or cause it?

Both, in different mouse models. Tumors fell in rats and mice given chemicals, and rose in mice bred to develop breast cancer. One small human report in colon and rectal cancer gave no numbers (Pliss et al., 2001; Anisimov et al., 2002; Ias’kevich et al., 2005).

Does Vilon extend lifespan?

A 2000 mouse report says treated mice lived longer, without a number. The 2001 paper’s survival gains were with Epitalon, and the 20 to 40% figure online is in no abstract we read (Khavinson et al., 2000; Anisimov et al., 2001).

Does Vilon help diabetes or lower insulin needs?

One 2007 Russian report in type 1 diabetes says the insulin dose needed was lower in most cases. The abstract gives no patient count or unit figure, and we found no full text (Kuznik et al., 2007).

Is Vilon the same as Thymalin?

No. Thymalin is a thymus extract; the group names KE (Vilon) and EW as its active substances (Linkova et al., 2023).

What is the molecular formula and weight of Vilon?

C11H21N3O5 and 275.30 daltons. A seller figure of C11H21N3O6 and 291.30 is one oxygen atom too heavy (PubChem).

Does Vilon lengthen telomeres?

Not shown. We found no study that measured telomere length after Vilon.

Can Vilon be stacked with Epitalon?

No study tested the pair for health, lifespan or tumors. One mouse study counted heart gene-activity changes: 36 clones for Vilon, 98 for Epitalon and 144 for both (Anisimov et al., 2002 (heart)).

Is Vilon FDA approved or legal?

It isn’t an approved drug, and the FDA’s approved-drug data return no product under its names (openFDA Drugs@FDA). Our guide to what to look for covers the routes people use.

What is the best anti-aging peptide?

No study has ranked them. Vilon’s anti-aging case rests mainly on one mouse report without numbers and dish work from one network (Khavinson et al., 2000; Lezhava et al., 2004).

Sources

  1. Kuznik BI, et al. [Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus]. Adv Gerontol. 2007;20(2):106-15. In Russian. PubMed 18306698
  2. Kuznik BI, et al. [Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age]. Adv Gerontol. 2006;19:107-15. In Russian. PubMed 17152731
  3. Ias'kevich LS, et al. [Application of peptide bioregulator in complex treatment of elderly cancer patients]. Adv Gerontol. 2005;16:97-100. In Russian. PubMed 16075684
  4. Lezhava T, et al. Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. Biogerontology. 2004;5(2):73-9. PubMed 15105581
  5. Khavinson VKh, et al. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004;137(1):78-81. PubMed 15085253
  6. Khavinson VK, et al. [KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging.]. Adv Gerontol. 2023;36(3):302-312. In Russian. PubMed 37782636
  7. Ashapkin V, et al. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. 2020;47(6):4323-4329. PubMed 32399807
  8. Fridman NV, et al. Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging. Bull Exp Biol Med. 2020;170(1):154-157. PubMed 33231794
  9. Avolio F, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022;23(7):3607. PubMed 35408963
  10. Linkova N, et al. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. Int J Mol Sci. 2023;24(17):13377. PubMed 37686182
  11. Khavinson VK, et al. Effect of vilon on biological age and lifespan in mice. Bull Exp Biol Med. 2000;130(7):687-90. PubMed 11140587
  12. Khavinson VKh, et al. A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice. Dokl Biol Sci. 2000;372:261-3. PubMed 10944717
  13. Anisimov VN, et al. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Mech Ageing Dev. 2001;122(1):41-68. PubMed 11163623
  14. Anisimov VN, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7-10. PubMed 12209581
  15. Alimova IN, et al. [Effect of Epitalon and Vilon treatment on mammary carcinogenesis in transgenic erbB-2/NEU mice]. Vopr Onkol. 2002;48(1):57-60. In Russian. PubMed 12101568
  16. Pliss GB, et al. Inhibitory effect of peptide vilon on the development of induced rat urinary bladder tumors in rats. Bull Exp Biol Med. 2001;131(6):558-60. PubMed 11586406
  17. Pliss GB, et al. [Effect of vilon and epithalone on induction and growth of induced bladder neoplasms in rats]. Vopr Onkol. 2001;47(5):601-7. In Russian. PubMed 11785104
  18. Pliss GB, et al. [The effect of vilon (Lys-Glu) on 1.2-dimethylhydrazine-induced neoplasia]. Vopr Onkol. 2005;51(4):466-9. In Russian. PubMed 16308980
  19. Khavinson VK, et al. Immunohistochemical and morphometric analysis of effects of vilon and epithalon on functional morphology of radiosensitive organs. Bull Exp Biol Med. 2001;131(3):285-92. PubMed 11427924
  20. Kniaz'kin IV, et al. [The effect of vilon on the thymus and spleen in a radiation model of premature aging]. Adv Gerontol. 2002;9:105-9. In Russian. PubMed 12096431
  21. Anisimov SV, et al. Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology. Bull Exp Biol Med. 2002;133(3):293-9. PubMed 12360356
  22. Khavinson VK, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PubMed 34834147
  23. Khavinson VKh, et al. [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]. Adv Gerontol. 2013;26(1):20-37. In Russian. PubMed 24003726
  24. Pinelis IS, et al. [Age features of bioregulatory therapy of dental diseases.]. Adv Gerontol. 2020;33(1):137-152. In Russian. PubMed 32362097
  25. ClinicalTrials.gov. Search for Vilon, November 12, 2026: no registered trial. Search
  26. U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for Vilon and lysylglutamic acid, November 12, 2026: no match. openFDA
  27. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  28. World Anti-Doping Agency. 2026 Prohibited List, section S0. WADA document
  29. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  30. National Library of Medicine. PubChem compound record: Lysylglutamic acid (CID 7010502). PubChem
  31. U.S. Food and Drug Administration. Global Substance Registration System: Lysylglutamic acid (UNII H34V7IM5ML). GSRS

Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.